Literature DB >> 28445661

Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.

Stephen L Hauser1, Shibeshih Belachew2, Ludwig Kappos3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28445661     DOI： 10.1056/NEJMc1702076

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

1.  Four cases of natalizumab-related PML: a less severe course in extended interval dosing?

Authors:  Cristina Scarpazza; Nicola De Rossi; Giulietta Tabiadon; Maria Vittoria Turrini; Simonetta Gerevini; Ruggero Capra
Journal:  Neurol Sci       Date:  2019-06-07       Impact factor: 3.307

Review 2.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

Review 3.  Contribution of Dysregulated B-Cells and IgE Antibody Responses to Multiple Sclerosis.

Authors:  Malik R Seals; Monica M Moran; Jonathan D Leavenworth; Jianmei W Leavenworth
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

Review 4.  Current advancements in promoting remyelination in multiple sclerosis.

Authors:  David Kremer; Rainer Akkermann; Patrick Küry; Ranjan Dutta
Journal:  Mult Scler       Date:  2018-10-01       Impact factor: 6.312

5.  Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys.

Authors:  Diethilde Theil; Paul Smith; Catherine Huck; Yoann Gilbart; Algirdas Kakarieka; David Leppert; Celine Rauld; Cindy Schmid; Reto Baumgartner; Nathalie Stuber; Francisco Cordoba; Valerie Dubost; Katy Darribat; Magali Jivkov; Wilfried Frieauff; Rainer Kneuer; Markus Stoeckli; Stefan Reinker; Keith Mansfield; José M Carballido; Philippe Couttet; Gisbert Weckbecker
Journal:  Front Immunol       Date:  2019-06-20       Impact factor: 7.561

6.  Efficient Distribution of a Novel Zirconium-89 Labeled Anti-cd20 Antibody Following Subcutaneous and Intravenous Administration in Control and Experimental Autoimmune Encephalomyelitis-Variant Mice.

Authors:  Mary-Anne Migotto; Karine Mardon; Jacqueline Orian; Gisbert Weckbecker; Rainer Kneuer; Rajiv Bhalla; David C Reutens
Journal:  Front Immunol       Date:  2019-10-18       Impact factor: 7.561

7.  B-cells expressing NgR1 and NgR3 are localized to EAE-induced inflammatory infiltrates and are stimulated by BAFF.

Authors:  Maha M Bakhuraysah; Paschalis Theotokis; Jae Young Lee; Amani A Alrehaili; Pei-Mun Aui; William A Figgett; Michael F Azari; John-Paul Abou-Afech; Fabienne Mackay; Christopher Siatskas; Frank Alderuccio; Stephen M Strittmatter; Nikolaos Grigoriadis; Steven Petratos
Journal:  Sci Rep       Date:  2021-02-03       Impact factor: 4.996

8.  N-Glycan Branching Decouples B Cell Innate and Adaptive Immunity to Control Inflammatory Demyelination.

Authors:  Christie-Lynn Mortales; Sung-Uk Lee; Armen Manousadjian; Ken L Hayama; Michael Demetriou
Journal:  iScience       Date:  2020-07-18

Review 9.  Monoclonal Antibody-Based Therapies for Myasthenia Gravis.

Authors:  Sawsan Alabbad; Mohanad AlGaeed; Patricia Sikorski; Henry J Kaminski
Journal:  BioDrugs       Date:  2020-10       Impact factor: 5.807

10.  Ataxin-1 regulates B cell function and the severity of autoimmune experimental encephalomyelitis.

Authors:  Alessandro Didonna; Ester Canto Puig; Qin Ma; Atsuko Matsunaga; Brenda Ho; Stacy J Caillier; Hengameh Shams; Nicholas Lee; Stephen L Hauser; Qiumin Tan; Scott S Zamvil; Jorge R Oksenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-02       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.